The HEAL project focuses on developing HLA-homozygous iPSC-derived cardiomyocyte aggregates for allogeneic cell therapy to treat heart failure. It aims to address challenges in iPSC-based therapies by creating scalable, GMP-compliant production and cryopreservation methods while minimizing immunosuppression needs. The project will also use immunogenicity assays to develop AI tools for predicting patients' immune responses.